2006•Chinese Clinical OncologyRequires access

Combination of nedaplatin and vinorelbine for treatment of non-small cell lung cancer clinical research

XU Zhi-fen

Abstract

Objective:To observe the efficacy and the side effects of nedaplatin in treatment of advanced non-small cell lung cancer (NSCLC).Methods:The patients with NSCLC by pathologic diagnosis were randomized to two groups: The observed group was treated with nedaplatin (80mg/m~2, iv, d_1) plus vinorelbine (NVB 25mg/m~2, iv, d_1, d_8, every 4 weeks), And the control group was treated with capsulation (DDP, 80mg/m~2, iv, d_1, or30mg/m~2, iv, d_1～d_3) plus vinorelbine (NVB 25mg/m~2, iv, d_1, d_8, every 4 weeks). Results:25 patients were in the observed group and 21 patients were in the control group, the response rates were 32.0% and 23.8%, respectively. The two groups had similar incidence rate of anemia, neutropenia and thrombocytopenia. But the incidence rate of vomiting was higher in the control group than that in the observed group (P0.05).Conclusion:Nedaplatin combined with vinorelbine is an effective and well tolerable regimen in the treatment of advanced NSCLC.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Nedaplatin, Vinorelbine, Medicine, Internal medicine, Lung cancer, Neutropenia, Regimen, Incidence (geometry)